ProKidney to Participate in the UBS Virtual Organ Restoration Day
ProKidney Corp. (Nasdaq: PROK), a late clinical-stage biotech company focusing on developing a first-in-class cell therapy for chronic kidney disease (CKD), has announced its participation in the UBS Virtual Organ Restoration Day on October 15, 2024. Senior management team members will engage in a fireside chat at 9:00am ET.
The event will be accessible via a live webcast, with a link provided for public viewing. Additionally, the webcast will be available through ProKidney's website in the 'Events' section of the Investor Relations tab. A replay will remain accessible for 90 days following the event.
ProKidney's management team will also conduct one-on-one meetings with investors during the event. Interested parties are advised to contact their UBS representative to arrange these meetings.
ProKidney Corp. (Nasdaq: PROK), un'azienda biotecnologica in fase clinica avanzata che si concentra sullo sviluppo di una terapia cellulare innovativa per la malattia renale cronica (CKD), ha annunciato la sua partecipazione alla Giornata Virtuale di Ripristino degli Organi UBS il 15 ottobre 2024. I membri del team di gestione senior parteciperanno a una conversazione informale alle 9:00 ET.
L'evento sarà accessibile tramite un webcast in diretta, con un link fornito per la visione pubblica. Inoltre, il webcast sarà disponibile attraverso il sito web di ProKidney nella sezione 'Eventi' della scheda Relazioni con gli Investitori. Una registrazione sarà accessibile per 90 giorni dopo l'evento.
Il team di gestione di ProKidney condurrà anche incontri individuali con gli investitori durante l'evento. Le parti interessate sono invitate a contattare il proprio rappresentante UBS per organizzare questi incontri.
ProKidney Corp. (Nasdaq: PROK), una empresa biotecnológica en etapa clínica avanzada dedicada al desarrollo de una terapia celular innovadora para la enfermedad renal crónica (CKD), ha anunciado su participación en el Día Virtual de Restauración de Órganos de UBS el 15 de octubre de 2024. Los miembros del equipo de alta dirección participarán en una charla informal a las 9:00 ET.
El evento será accesible a través de un webcast en vivo, con un enlace proporcionado para la visualización pública. Además, el webcast estará disponible en el sitio web de ProKidney en la sección 'Eventos' de la pestaña de Relaciones con Inversores. Se mantendrá disponible una grabación durante 90 días después del evento.
El equipo de gestión de ProKidney también llevará a cabo reuniones individuales con inversores durante el evento. Se aconseja a las partes interesadas que contacten a su representante de UBS para coordinar estas reuniones.
ProKidney Corp. (Nasdaq: PROK)는 만성 신장 질환(CKD)에 대한 1급 셀 치료제를 개발하는 임상 후 단계의 생명공학 회사로, 2024년 10월 15일에 있을 UBS 가상 장기 복원 일에 참여한다고 발표했습니다. 고위 경영진이 오전 9:00 ET에 대화에 참여할 것입니다.
이 행사는 공개 시청을 위한 링크와 함께 라이브 웹캐스트를 통해 접근할 수 있습니다. 또한, 웹캐스트는 ProKidney의 웹사이트 '투자자 관계' 탭의 '이벤트' 섹션을 통해 제공됩니다. 이벤트 후 90일 동안 재생할 수 있는 녹화본도 제공됩니다.
ProKidney의 경영진은 행사 중 투자자와 개별 미팅을 진행할 예정입니다. 관심 있는 분들은 UBS 대표에게 이 미팅을 요청하실 것을 권장합니다.
ProKidney Corp. (Nasdaq: PROK), une entreprise biopharmaceutique en phase clinique avancée axée sur le développement d'une thérapie cellulaire de pointe pour la maladie rénale chronique (CKD), a annoncé sa participation à la Journée de Restauration Virtuelle des Organes UBS le 15 octobre 2024. Les membres de l'équipe de direction senior participeront à une discussion informelle à 9h00 ET.
L'événement sera accessible via un webcast en direct, avec un lien fourni pour la visualisation publique. De plus, le webcast sera disponible sur le site web de ProKidney dans la section 'Événements' de l'onglet Relations Investisseurs. Un enregistrement sera accessible pendant 90 jours après l'événement.
L'équipe de direction de ProKidney organisera également des réunions individuelles avec les investisseurs lors de l'événement. Les parties intéressées sont invitées à contacter leur représentant UBS pour organiser ces réunions.
ProKidney Corp. (Nasdaq: PROK), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung einer bahnbrechenden Zelltherapie für chronische Nierenerkrankungen (CKD) konzentriert, hat seine Teilnahme am UBS Virtual Organ Restoration Day am 15. Oktober 2024 angekündigt. Mitglieder des Senior Management-Teams werden um 9:00 Uhr ET an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird über einen Live-Webcast zugänglich sein, mit einem Link für die öffentliche Betrachtung. Darüber hinaus wird der Webcast auf der Website von ProKidney im Abschnitt 'Veranstaltungen' unter der Rubrik Investor Relations verfügbar sein. Eine Aufzeichnung wird für 90 Tage nach der Veranstaltung verfügbar sein.
Das Management-Team von ProKidney wird während der Veranstaltung auch Einzelgespräche mit Investoren führen. Interessierte Parteien werden gebeten, sich an ihren UBS-Vertreter zu wenden, um diese Gespräche zu organisieren.
- None.
- None.
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024.
| UBS Virtual Organ Restoration Day | ||
| Date: | Tuesday, October 15, 2024 | |
| Time: | 9:00am ET | |
| Format: | Fireside Chat | |
| Webcast Link: | https://kvgo.com/ubs/prokidney-oct-2024 | |
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the fireside chat, a replay of the webcast will be available for 90 days.
The ProKidney management team will also host one-on-one meetings during this event. Interested investors should contact their UBS representative to schedule meetings.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) participating in the UBS Virtual Organ Restoration Day?
What time is ProKidney's (PROK) fireside chat at the UBS Virtual Organ Restoration Day?
How can investors access ProKidney's (PROK) presentation at the UBS Virtual Organ Restoration Day?
How long will the replay of ProKidney's (PROK) UBS Virtual Organ Restoration Day presentation be available?
What is ProKidney's (PROK) main focus in biotechnology?
